Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.30 USD

76.30
442,112

+1.53 (2.05%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $76.35 +0.05 (0.07%) 7:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Haemonetics (HAE) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 7.22% and 4.13%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CVS Health (CVS) Q4 Earnings Top Estimates, 2024 EPS View Down

by Zacks Equity Research

Robust sales growth across all three operating segments contributes to CVS Health's (CVS) Q4 revenues.

Zacks Equity Research

Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip

by Zacks Equity Research

Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.

Zacks Equity Research

VAREX IMAGING (VREX) Lags Q1 Earnings Estimates

by Zacks Equity Research

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -45.45% and 0.85%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HAE vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

HAE vs. ABT: Which Stock Is the Better Value Option?

Zacks Equity Research

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

by Zacks Equity Research

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Strength of the base business bodes well for Quest Diagnostics (DGX).

Zacks Equity Research

IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Zacks Equity Research

Hologic's (HOLX) Q1 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Hologic's (HOLX) Breast Health segment registered strong growth in Q1, primarily owing to higher capital equipment revenues.

Zacks Equity Research

Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod

by Zacks Equity Research

Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.

Zacks Equity Research

Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout

by Zacks Equity Research

Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.

Derek Lewis headshot

3 Stocks to Buy for Consistent Sales Growth

by Derek Lewis

Consistency is key, particularly whenever it concerns generating sales. For those seeking top line compounders, these three companies fit the criteria nicely.

Zacks Equity Research

Insulet (PODD) Gains From Product Innovation, Global Expansion

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Zacks Equity Research

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down

by Zacks Equity Research

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.

Zacks Equity Research

Align Technology (ALGN) Q4 Revenues Top, Margins Expand

by Zacks Equity Research

Align Technology (ALGN) surpasses revenue and earnings estimates in the fourth quarter of fiscal 2023.

Zacks Equity Research

Is Haemonetics (HAE) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls

by Zacks Equity Research

Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.

Zacks Equity Research

Thermo Fisher (TMO) End Market Growth Strong Despite Macro Woes

by Zacks Equity Research

Thermo Fisher's (TMO) electron microscopy, chromatography and mass spectrometry businesses are delivering strong growth in the academic and government end market.

Zacks Equity Research

QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences

by Zacks Equity Research

QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.

Zacks Equity Research

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.

Zacks Equity Research

Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise

by Zacks Equity Research

Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.